PD1 antibody
Phase 3Small molecule
PD1 antibody is one of 19 small molecule programs targeting Endometrial Carcinoma. It is currently in Phase 3.
1
Indications
4
Total Trials
1
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
21 competitors in Endometrial Carcinoma
#DrugCompanyPhaseTrials
1Lynparza
AstraZenecaApproved
Taxol
TevaPhase 3
Keytruda
Merck & Co.Phase 3
IC-Green
PProvepharm SAS
Approved
Megace
Bristol-Myers SquibbPhase 3
Depo-Provera
Eli LillyPhase 3
Femara
NovartisPhase 2
Afinitor
NovartisPhase 2
Kisqali
NovartisPhase 2
Trodelvy
GileadPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced1 trial
Endometrial Carcinoma1 trial
Patients With Advanced Solid Tumors1 trial
Lenalidomide1 trial
PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV
Unknown status·—·Phase 3·NCT04084626·40 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PD1 antibody. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- HHRYZ Biotech Co.